Lineage Cell Therapeutics (LCTX)

• Market cap: $295M
• 1 day: 10.26%
• 5 days: 3.20%
• 1 month: 10.26%
• 3 months: 88.90%
• 6 months: 105.91%
• Year to date: 150.49%
• 1 year: 41.45%
• 5 years: 43.33%
• 10 years: -43.42%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Employees: 77

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

77% more capital invested

Capital invested by funds: $49.7M [Q1] → $87.9M (+$38.2M) [Q2]

50% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]

9% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 32

1% more funds holding

Funds holding: 127 [Q1] → 128 (+1) [Q2]

5.3% less ownership

Funds ownership: 47.89% [Q1] → 42.59% (-5.3%) [Q2]

37% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 35

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2 55% upside
• Avg. target: $5.50 326% upside
• High target: $9 598% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert	55% upside $2	Buy Maintained	14 Aug 2025
HC Wainwright & Co. Joseph Pantginis	598% upside $9	Buy Reiterated	23 Jun 2025